CompetitionThe LY3866288 molecule is less potent and less selective for FGFR3 compared to TYRA-300, with higher toxicity rates, posing competitive challenges.
DosingThe twice-daily dosing regimen of LY3866288 is less preferable compared to the once-daily regimen of TYRA-300, creating a potential downside in patient adherence.
Safety ConcernsThe safety profile looked encouraging, with evidence of less FGFR1- and FGFR2-specific toxicities observed compared to Johnson & Johnson's Balversa, though safety remains a critical consideration.